Sana Biotechnology, Inc. (SANA) – What Are Investment Firms Saying About This Stock?

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $9.60.

SANA has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. Bank of America dropped their target price on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, August 14th. TD Cowen upgraded Sana Biotechnology to a “strong-buy” rating in a report on Monday, August 24th. Finally, Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th.

Sana Biotechnology Price Performance

SANA opened at $2.44 on Wednesday. The stock has a market capitalization of $730.44 million, a P/E ratio of -3.21 and a beta of 2.30. The company’s 50 day simple moving average is $2.98 and its 200-day simple moving average is $3.38. Sana Biotechnology has a one year low of $2.22 and a one year high of $5.49.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. As a group, analysts anticipate that Sana Biotechnology will post -0.72 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SANA. Walleye Capital LLC acquired a new position in Sana Biotechnology in the second quarter valued at approximately $35,000. Royal Bank of Canada boosted its stake in Sana Biotechnology by 76.8% in the first quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock valued at $35,000 after acquiring an additional 5,338 shares during the last quarter. Abel Hall LLC acquired a new stake in Sana Biotechnology during the 3rd quarter worth $35,000. Rockefeller Capital Management L.P. grew its holdings in Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after acquiring an additional 4,088 shares during the period. Finally, Leonteq Securities AG acquired a new stake in Sana Biotechnology during the 1st quarter worth $43,000. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.